Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesothelioma Malignant Advanced
Conditions
Pleural Mesothelioma Malignant Advanced
Trial Timeline
Apr 30, 2019 → Nov 18, 2024
NCT ID
NCT03762018About Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab is a phase 3 stage product being developed by Roche for Pleural Mesothelioma Malignant Advanced. The current trial status is completed. This product is registered under clinical trial identifier NCT03762018. Target conditions include Pleural Mesothelioma Malignant Advanced.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03762018 | Phase 3 | Completed |
Competing Products
20 competing products in Pleural Mesothelioma Malignant Advanced